Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 509

The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.

Convalescent Plasma Antibody Levels and the Risk of Death from Covid-19

Open access
Joyner, Michael J., Carter, Rickey E., Senefeld, Jonathon W., Klassen, Stephen A., Mills, John R., Johnson, Patrick W., Theel, Elitza S., Wiggins, Chad C., Bruno, Katelyn A., Klompas, Allan M., Lesser, Elizabeth R., Kunze, Katie L., Sexton, Matthew A., Diaz Soto, Juan C., Baker, Sarah E., Shepherd, John R.A., van Helmond, Noud, Verdun, Nicole C., Marks, Peter, van Buskirk, Camille M., Winters, Jeffrey L., Stubbs, James R., Rea, Robert F., Hodge, David O., Herasevich, Vitaly, Whelan, Emily R., Clayburn, Andrew J., Larson, Kathryn F., Ripoll, Juan G., Andersen, Kylie J., Buras, Matthew R., Vogt, Matthew N.P., Dennis, Joshua J., Regimbal, Riley J., Bauer, Philippe R., Blair, Janis E., Paneth, Nigel S., Fairweather, DeLisa, Wright, R. Scott, Casadevall, Arturo·2021·New England Journal of Medicine

Abstract

BACKGROUND: Convalescent plasma has been widely used to treat coronavirus disease 2019 (Covid-19) under the presumption that such plasma contains potentially therapeutic antibodies to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that can be passively transferred to the plasma recipient. Whether convalescent plasma with high antibody levels rather than low antibody levels is associated with a lower risk of death is unknown. METHODS: In a retrospective study based on a U.S. national registry, we determined the anti-SARS-CoV-2 IgG antibody levels in convalescent plasma used to treat hospitalized adults with Covid-19. The primary outcome was death within 30 days after plasma transfusion. Patients who were enrolled through July 4, 2020, and for whom data on anti-SARS-CoV-2 antibody levels in plasma transfusions and on 30-day mortality were available were included in the analysis. RESULTS: Of the 3082 patients included in this analysis, death within 30 days after plasma transfusion occurred in 115 of 515 patients (22.3%) in the high-titer group, 549 of 2006 patients (27.4%) in the medium-titer group, and 166 of 561 patients (29.6%) in the low-titer group. The association of anti-SARS-CoV-2 antibody levels with the risk of death from Covid-19 was moderated by mechanical ventilation status. A lower risk of death within 30 days in the high-titer group than in the low-titer group was observed among patients who had not received mechanical ventilation before transfusion (relative risk, 0.66; 95% confidence interval [CI], 0.48 to 0.91), and no effect on the risk of death was observed among patients who had received mechanical ventilation (relative risk, 1.02; 95% CI, 0.78 to 1.32). CONCLUSIONS: Among patients hospitalized with Covid-19 who were not receiving mechanical ventilation, transfusion of plasma with higher anti-SARS-CoV-2 IgG antibody levels was associated with a lower risk of death than transfusion of plasma with lower antibody levels. (Funded by the Department of Health and Human Services and others; ClinicalTrials.gov number, NCT04338360.).

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejmoa2031893

Cites

32 of 32 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 32 references

Cited by

See all 509

Metadata

Authors
Joyner, M. J., Carter, R. E., Senefeld, J. W., Klassen, S. A., Mills, J. R., Johnson, P. W., Theel, E. S., Wiggins, C. C., Bruno, K. A., Klompas, A. M., Lesser, E. R., Kunze, K. L., Sexton, M. A., Diaz Soto, J. C., Baker, S. E., Shepherd, J. R. A., van Helmond, N., Verdun, N. C., Marks, P., van Buskirk, C. M., Winters, J. L., Stubbs, J. R., Rea, R. F., Hodge, D. O., Herasevich, V., Whelan, E. R., Clayburn, A. J., Larson, K. F., Ripoll, J. G., Andersen, K. J., Buras, M. R., Vogt, M. N. P., Dennis, J. J., Regimbal, R. J., Bauer, P. R., Blair, J. E., Paneth, N. S., Fairweather, D., Wright, R. S., & Casadevall, A.
Venue
New England Journal of Medicine
Published
2021-03-18
Volume
384
Issue
11
Pages
1015-1027
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W3118278606
Cited by
509
References
32
FWCI
36.13
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Convalescent Plasma Antibody Levels and the Risk of Death from Covid-19. https://app.cochat.ai/papers/10.1056/nejmoa2031893
The paper
Joyner, M. J., Carter, R. E., Senefeld, J. W., Klassen, S. A., Mills, J. R., Johnson, P. W., Theel, E. S., Wiggins, C. C., Bruno, K. A., Klompas, A. M., Lesser, E. R., Kunze, K. L., Sexton, M. A., Diaz Soto, J. C., Baker, S. E., Shepherd, J. R. A., van Helmond, N., Verdun, N. C., Marks, P., . . . Casadevall, A. (2021). Convalescent Plasma Antibody Levels and the Risk of Death from Covid-19. New England Journal of Medicine. https://doi.org/10.1056/nejmoa2031893

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.